The Motley Fool

Why AstraZeneca Plc Is A Buy For Me

Pharmaceutical company AstraZeneca (LSE: AZN) (NYSE: AZN.US) has been in the doldrums for a while now. The company’s share price has been becalmed by a succession of patent expiries and lack of successes in its drugs pipeline.

Last year the patent on Seroquel expired, and next year the patent on heartburn drug Nexium expires. The loss of exclusivity of these blockbusters has meant that sales and profits have been falling.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

More innovative and less risk-averse

The lack of a clear strategy to reverse this decline cost chief executive Dave Brennan his job. But new chief executive Pascal Soriot has shown an impressive ability to sort out AstraZeneca’s troubles and reshape it as a company with a focus on areas that promise growth in the future.

He is encouraging the company to be more innovative, basing the company’s research activities in the buzzing ‘life sciences’ hub of Cambridge, which Soriot thinks could rival San Francisco and Boston. His aim is that the business feeds off this entrepreneurial spirit and is less risk-averse and more ambitious.

He is making considered acquisitions, often of biotech companies with bright ideas but small pockets, and he is focusing research in the areas of cardiovascular medicine, oncology and respiratory drugs.

A more future-proof company

He is a former executive of Roche, which, of all drugs companies, has been quickest off the mark in embracing the new boom in biologics and biotechnology. If Astra can future-proof itself in a similar way, then this company may just be a great turnaround opportunity.

The simple numbers show why AstraZeneca is a buy: the company is on a forward P/E ratio of just 9 (compared to 14 for GlaxoSmithKline), with a dividend yield of 6%. With profitability now stabilising after all the patent expiries, and with routes to growth such as emerging markets and biotech, this is a value/turnaround play with the potential for long-term growth.

For all these reasons, AstraZeneca is a buy.

One of the value plays of the year?

Personally, as an investor, value investing forms the central tenet of my investing philosophy. AstraZeneca’s low P/E ratio and high dividend yield make it one of the value and income plays of the moment.

If you already own AstraZeneca shares and are looking for more investing ideas, then I’d recommend you read our report “The Motley Fool’s Top Income Share For 2013”. It has been put together by our resident investing experts and is available without obligation and completely free.

> Prabhat owns shares in GlaxoSmithKline, but owns none of the other shares in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.